nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Blood pressure systolic increased—Sorafenib—thyroid cancer	0.0977	0.126	CcSEcCtD
Dextroamphetamine—Sudden death—Vandetanib—thyroid cancer	0.0411	0.0528	CcSEcCtD
Dextroamphetamine—TAAR1—neck—thyroid cancer	0.0382	0.414	CbGeAlD
Dextroamphetamine—TAAR1—thyroid gland—thyroid cancer	0.0182	0.197	CbGeAlD
Dextroamphetamine—Blood pressure increased—Sorafenib—thyroid cancer	0.0142	0.0182	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.012	0.0155	CcSEcCtD
Dextroamphetamine—Weight decreased—Vandetanib—thyroid cancer	0.0119	0.0153	CcSEcCtD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—RET—thyroid cancer	0.0118	0.091	CbGpPWpGaD
Dextroamphetamine—Depression—Vandetanib—thyroid cancer	0.0117	0.0151	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.0117	0.015	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Vandetanib—thyroid cancer	0.0114	0.0147	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—CALCB—thyroid cancer	0.0105	0.0814	CbGpPWpGaD
Dextroamphetamine—Cardiomyopathy—Epirubicin—thyroid cancer	0.0102	0.0132	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Vandetanib—thyroid cancer	0.00998	0.0128	CcSEcCtD
Dextroamphetamine—Mood swings—Sorafenib—thyroid cancer	0.00975	0.0125	CcSEcCtD
Dextroamphetamine—Cardiomyopathy—Doxorubicin—thyroid cancer	0.00947	0.0122	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Sorafenib—thyroid cancer	0.0094	0.0121	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00927	0.0119	CcSEcCtD
Dextroamphetamine—Tremor—Vandetanib—thyroid cancer	0.00861	0.0111	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00819	0.0105	CcSEcCtD
Dextroamphetamine—Weight decreased—Sorafenib—thyroid cancer	0.00805	0.0103	CcSEcCtD
Dextroamphetamine—Convulsion—Vandetanib—thyroid cancer	0.00796	0.0102	CcSEcCtD
Dextroamphetamine—Hypertension—Vandetanib—thyroid cancer	0.00793	0.0102	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00786	0.0101	CcSEcCtD
Dextroamphetamine—Chest pain—Vandetanib—thyroid cancer	0.00782	0.01	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00782	0.01	CcSEcCtD
Dextroamphetamine—Anxiety—Vandetanib—thyroid cancer	0.0078	0.01	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Sorafenib—thyroid cancer	0.00777	0.00999	CcSEcCtD
Dextroamphetamine—Dry mouth—Vandetanib—thyroid cancer	0.00765	0.00983	CcSEcCtD
Dextroamphetamine—Infection—Vandetanib—thyroid cancer	0.00745	0.00957	CcSEcCtD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—RET—thyroid cancer	0.00702	0.0542	CbGpPWpGaD
Dextroamphetamine—Insomnia—Vandetanib—thyroid cancer	0.00678	0.00871	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Sorafenib—thyroid cancer	0.00673	0.00865	CcSEcCtD
Dextroamphetamine—Dyspnoea—Vandetanib—thyroid cancer	0.00669	0.00859	CcSEcCtD
Dextroamphetamine—Dyspepsia—Vandetanib—thyroid cancer	0.0066	0.00848	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vandetanib—thyroid cancer	0.00652	0.00837	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00647	0.00832	CcSEcCtD
Dextroamphetamine—Fatigue—Vandetanib—thyroid cancer	0.00646	0.0083	CcSEcCtD
Dextroamphetamine—Constipation—Vandetanib—thyroid cancer	0.00641	0.00824	CcSEcCtD
Dextroamphetamine—SLC18A2—thyroid gland—thyroid cancer	0.00617	0.067	CbGeAlD
Dextroamphetamine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00613	0.00788	CcSEcCtD
Dextroamphetamine—Body temperature increased—Vandetanib—thyroid cancer	0.00593	0.00761	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vandetanib—thyroid cancer	0.00593	0.00761	CcSEcCtD
Dextroamphetamine—Viral infection—Epirubicin—thyroid cancer	0.0058	0.00745	CcSEcCtD
Dextroamphetamine—Angioedema—Sorafenib—thyroid cancer	0.00566	0.00728	CcSEcCtD
Dextroamphetamine—Dyskinesia—Epirubicin—thyroid cancer	0.00558	0.00716	CcSEcCtD
Dextroamphetamine—ADRA1B—head—thyroid cancer	0.00553	0.06	CbGeAlD
Dextroamphetamine—SLC18A2—head—thyroid cancer	0.00548	0.0594	CbGeAlD
Dextroamphetamine—Asthenia—Vandetanib—thyroid cancer	0.00538	0.00691	CcSEcCtD
Dextroamphetamine—Viral infection—Doxorubicin—thyroid cancer	0.00537	0.0069	CcSEcCtD
Dextroamphetamine—Hypertension—Sorafenib—thyroid cancer	0.00535	0.00687	CcSEcCtD
Dextroamphetamine—Dry mouth—Sorafenib—thyroid cancer	0.00516	0.00663	CcSEcCtD
Dextroamphetamine—Dyskinesia—Doxorubicin—thyroid cancer	0.00516	0.00663	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vandetanib—thyroid cancer	0.00513	0.00659	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00506	0.0065	CcSEcCtD
Dextroamphetamine—Infection—Sorafenib—thyroid cancer	0.00503	0.00646	CcSEcCtD
Dextroamphetamine—Dizziness—Vandetanib—thyroid cancer	0.00496	0.00637	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—TSHR—thyroid cancer	0.00488	0.0377	CbGpPWpGaD
Dextroamphetamine—Anorexia—Sorafenib—thyroid cancer	0.00482	0.00619	CcSEcCtD
Dextroamphetamine—Vomiting—Vandetanib—thyroid cancer	0.00477	0.00612	CcSEcCtD
Dextroamphetamine—Rash—Vandetanib—thyroid cancer	0.00473	0.00607	CcSEcCtD
Dextroamphetamine—Dermatitis—Vandetanib—thyroid cancer	0.00472	0.00607	CcSEcCtD
Dextroamphetamine—Headache—Vandetanib—thyroid cancer	0.0047	0.00603	CcSEcCtD
Dextroamphetamine—Dyspnoea—Sorafenib—thyroid cancer	0.00451	0.00579	CcSEcCtD
Dextroamphetamine—Nausea—Vandetanib—thyroid cancer	0.00445	0.00572	CcSEcCtD
Dextroamphetamine—Dyspepsia—Sorafenib—thyroid cancer	0.00445	0.00572	CcSEcCtD
Dextroamphetamine—Decreased appetite—Sorafenib—thyroid cancer	0.0044	0.00565	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00437	0.00561	CcSEcCtD
Dextroamphetamine—Fatigue—Sorafenib—thyroid cancer	0.00436	0.0056	CcSEcCtD
Dextroamphetamine—Constipation—Sorafenib—thyroid cancer	0.00433	0.00556	CcSEcCtD
Dextroamphetamine—SLC6A3—head—thyroid cancer	0.00414	0.045	CbGeAlD
Dextroamphetamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00414	0.00531	CcSEcCtD
Dextroamphetamine—Urticaria—Sorafenib—thyroid cancer	0.00402	0.00516	CcSEcCtD
Dextroamphetamine—Abdominal pain—Sorafenib—thyroid cancer	0.004	0.00514	CcSEcCtD
Dextroamphetamine—Body temperature increased—Sorafenib—thyroid cancer	0.004	0.00514	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00388	0.00499	CcSEcCtD
Dextroamphetamine—SLC18A2—lymph node—thyroid cancer	0.00383	0.0416	CbGeAlD
Dextroamphetamine—TAAR1—GPCR ligand binding—CALCB—thyroid cancer	0.00382	0.0295	CbGpPWpGaD
Dextroamphetamine—Affect lability—Epirubicin—thyroid cancer	0.00374	0.00481	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Sorafenib—thyroid cancer	0.00373	0.00479	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—CALCA—thyroid cancer	0.00365	0.0282	CbGpPWpGaD
Dextroamphetamine—Asthenia—Sorafenib—thyroid cancer	0.00363	0.00466	CcSEcCtD
Dextroamphetamine—Mood swings—Epirubicin—thyroid cancer	0.0036	0.00463	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00359	0.00461	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Epirubicin—thyroid cancer	0.00347	0.00446	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—thyroid cancer	0.00346	0.00445	CcSEcCtD
Dextroamphetamine—Diarrhoea—Sorafenib—thyroid cancer	0.00346	0.00445	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00342	0.0044	CcSEcCtD
Dextroamphetamine—Dizziness—Sorafenib—thyroid cancer	0.00334	0.0043	CcSEcCtD
Dextroamphetamine—SLC6A2—head—thyroid cancer	0.00334	0.0363	CbGeAlD
Dextroamphetamine—Mood swings—Doxorubicin—thyroid cancer	0.00333	0.00428	CcSEcCtD
Dextroamphetamine—Vomiting—Sorafenib—thyroid cancer	0.00322	0.00413	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00321	0.00413	CcSEcCtD
Dextroamphetamine—Rash—Sorafenib—thyroid cancer	0.00319	0.0041	CcSEcCtD
Dextroamphetamine—Dermatitis—Sorafenib—thyroid cancer	0.00319	0.00409	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00317	0.00407	CcSEcCtD
Dextroamphetamine—Headache—Sorafenib—thyroid cancer	0.00317	0.00407	CcSEcCtD
Dextroamphetamine—ADRA1A—head—thyroid cancer	0.00311	0.0337	CbGeAlD
Dextroamphetamine—Nausea—Sorafenib—thyroid cancer	0.003	0.00386	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.003	0.00385	CcSEcCtD
Dextroamphetamine—Weight decreased—Epirubicin—thyroid cancer	0.00297	0.00382	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00291	0.00373	CcSEcCtD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00289	0.0223	CbGpPWpGaD
Dextroamphetamine—Urinary tract infection—Epirubicin—thyroid cancer	0.00285	0.00366	CcSEcCtD
Dextroamphetamine—Sweating—Epirubicin—thyroid cancer	0.00281	0.00361	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00278	0.00357	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—thyroid cancer	0.00275	0.00354	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00269	0.00345	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—thyroid cancer	0.00264	0.00339	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—thyroid cancer	0.0026	0.00334	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Epirubicin—thyroid cancer	0.00249	0.0032	CcSEcCtD
Dextroamphetamine—ADRA1A—Endothelin Pathways—CALCA—thyroid cancer	0.00237	0.0183	CbGpPWpGaD
Dextroamphetamine—SLC6A2—lymph node—thyroid cancer	0.00234	0.0254	CbGeAlD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00233	0.018	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Doxorubicin—thyroid cancer	0.0023	0.00296	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—thyroid cancer	0.00225	0.00289	CcSEcCtD
Dextroamphetamine—Nervousness—Epirubicin—thyroid cancer	0.00222	0.00286	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CALCB—thyroid cancer	0.00216	0.0167	CbGpPWpGaD
Dextroamphetamine—Agitation—Epirubicin—thyroid cancer	0.0021	0.0027	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—thyroid cancer	0.00208	0.00267	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—thyroid cancer	0.00206	0.00264	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—thyroid cancer	0.00202	0.0026	CcSEcCtD
Dextroamphetamine—Convulsion—Epirubicin—thyroid cancer	0.00198	0.00255	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—thyroid cancer	0.00198	0.00254	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—CALCB—thyroid cancer	0.00196	0.0152	CbGpPWpGaD
Dextroamphetamine—Chest pain—Epirubicin—thyroid cancer	0.00195	0.00251	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—thyroid cancer	0.00195	0.0025	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00195	0.015	CbGpPWpGaD
Dextroamphetamine—Anxiety—Epirubicin—thyroid cancer	0.00194	0.0025	CcSEcCtD
Dextroamphetamine—Dry mouth—Epirubicin—thyroid cancer	0.00191	0.00245	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—thyroid cancer	0.00187	0.00241	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00187	0.0024	CcSEcCtD
Dextroamphetamine—Infection—Epirubicin—thyroid cancer	0.00186	0.00239	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—thyroid cancer	0.00184	0.00236	CcSEcCtD
Dextroamphetamine—CYP2D6—head—thyroid cancer	0.00183	0.0199	CbGeAlD
Dextroamphetamine—Hypertension—Doxorubicin—thyroid cancer	0.00183	0.00235	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—thyroid cancer	0.00182	0.00234	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00181	0.014	CbGpPWpGaD
Dextroamphetamine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00181	0.00232	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—thyroid cancer	0.0018	0.00232	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—thyroid cancer	0.0018	0.00231	CcSEcCtD
Dextroamphetamine—Anorexia—Epirubicin—thyroid cancer	0.00178	0.00229	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—TSHR—thyroid cancer	0.00177	0.0137	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Doxorubicin—thyroid cancer	0.00176	0.00227	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00173	0.00222	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00172	0.0133	CbGpPWpGaD
Dextroamphetamine—Infection—Doxorubicin—thyroid cancer	0.00172	0.00221	CcSEcCtD
Dextroamphetamine—Insomnia—Epirubicin—thyroid cancer	0.00169	0.00217	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—thyroid cancer	0.00169	0.00217	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00167	0.00215	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—thyroid cancer	0.00167	0.00214	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—thyroid cancer	0.00166	0.00213	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—thyroid cancer	0.00165	0.00212	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—thyroid cancer	0.00165	0.00211	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—thyroid cancer	0.00163	0.00209	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00161	0.00207	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—thyroid cancer	0.00161	0.00207	CcSEcCtD
Dextroamphetamine—Constipation—Epirubicin—thyroid cancer	0.0016	0.00205	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—thyroid cancer	0.00156	0.00201	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—thyroid cancer	0.00154	0.00198	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—thyroid cancer	0.00154	0.00198	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00153	0.00196	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—thyroid cancer	0.00152	0.00196	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTCH1—thyroid cancer	0.00151	0.0116	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Doxorubicin—thyroid cancer	0.0015	0.00193	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00149	0.00192	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—thyroid cancer	0.00149	0.00192	CcSEcCtD
Dextroamphetamine—Urticaria—Epirubicin—thyroid cancer	0.00149	0.00191	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—thyroid cancer	0.00148	0.0019	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—thyroid cancer	0.00148	0.0019	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—thyroid cancer	0.00148	0.0019	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00141	0.00182	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—thyroid cancer	0.00138	0.00177	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—SST—thyroid cancer	0.00138	0.0106	CbGpPWpGaD
Dextroamphetamine—Urticaria—Doxorubicin—thyroid cancer	0.00137	0.00177	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—thyroid cancer	0.00137	0.00176	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—thyroid cancer	0.00137	0.00176	CcSEcCtD
Dextroamphetamine—Asthenia—Epirubicin—thyroid cancer	0.00134	0.00172	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CALCA—thyroid cancer	0.00133	0.0102	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00131	0.0102	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00131	0.0102	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Epirubicin—thyroid cancer	0.00128	0.00164	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00127	0.00164	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—thyroid cancer	0.00124	0.00159	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—thyroid cancer	0.00124	0.00159	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—thyroid cancer	0.00119	0.00153	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—thyroid cancer	0.00118	0.00152	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—thyroid cancer	0.00118	0.00151	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—thyroid cancer	0.00118	0.00151	CcSEcCtD
Dextroamphetamine—Headache—Epirubicin—thyroid cancer	0.00117	0.0015	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—CALCB—thyroid cancer	0.00116	0.00896	CbGpPWpGaD
Dextroamphetamine—Dizziness—Doxorubicin—thyroid cancer	0.00114	0.00147	CcSEcCtD
Dextroamphetamine—Nausea—Epirubicin—thyroid cancer	0.00111	0.00143	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—thyroid cancer	0.0011	0.00141	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—TRIM33—thyroid cancer	0.0011	0.00849	CbGpPWpGaD
Dextroamphetamine—Rash—Doxorubicin—thyroid cancer	0.00109	0.0014	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—thyroid cancer	0.00109	0.0014	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.00109	0.0084	CbGpPWpGaD
Dextroamphetamine—Headache—Doxorubicin—thyroid cancer	0.00108	0.00139	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC5A5—thyroid cancer	0.00105	0.00811	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.00105	0.0081	CbGpPWpGaD
Dextroamphetamine—Nausea—Doxorubicin—thyroid cancer	0.00103	0.00132	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—TSHR—thyroid cancer	0.001	0.00773	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000984	0.0076	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CALCB—thyroid cancer	0.000968	0.00747	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.000931	0.00719	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC5A5—thyroid cancer	0.00093	0.00719	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—TSHR—thyroid cancer	0.000909	0.00702	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000894	0.00691	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000884	0.00683	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000884	0.00683	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—RXRA—thyroid cancer	0.000882	0.00682	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CALCB—thyroid cancer	0.000859	0.00664	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000783	0.00605	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000783	0.00605	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—RXRA—thyroid cancer	0.000782	0.00604	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—SST—thyroid cancer	0.000778	0.00601	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000773	0.00597	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—NRG1—thyroid cancer	0.000763	0.0059	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000749	0.00579	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000746	0.00576	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000733	0.00567	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—SST—thyroid cancer	0.000707	0.00546	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CALCA—thyroid cancer	0.00068	0.00526	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—NRG1—thyroid cancer	0.000676	0.00522	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000668	0.00516	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000668	0.00516	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000662	0.00511	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000657	0.00508	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000627	0.00484	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CDK1—thyroid cancer	0.000616	0.00476	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000605	0.00467	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000588	0.00454	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000586	0.00453	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CALCB—thyroid cancer	0.000547	0.00422	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000538	0.00416	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TSHR—thyroid cancer	0.000537	0.00415	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000528	0.00408	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000522	0.00404	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MEN1—thyroid cancer	0.000505	0.0039	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.0005	0.00386	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CALCB—thyroid cancer	0.000497	0.00384	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CALCB—thyroid cancer	0.000486	0.00375	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—BRAF—thyroid cancer	0.00048	0.00371	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000478	0.00369	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000457	0.00353	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTCH1—thyroid cancer	0.000456	0.00353	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000449	0.00347	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000449	0.00347	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TSHR—thyroid cancer	0.000448	0.00346	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000442	0.00342	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CALCB—thyroid cancer	0.000441	0.00341	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00042	0.00324	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SST—thyroid cancer	0.000417	0.00323	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000406	0.00314	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CALCA—thyroid cancer	0.000402	0.0031	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000398	0.00308	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000398	0.00308	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TSHR—thyroid cancer	0.000398	0.00307	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000392	0.00303	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTCH1—thyroid cancer	0.000381	0.00294	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000374	0.00289	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—HRAS—thyroid cancer	0.000372	0.00288	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—thyroid cancer	0.000367	0.00283	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDK1—thyroid cancer	0.000364	0.00281	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—SST—thyroid cancer	0.000348	0.00269	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTCH1—thyroid cancer	0.000338	0.00261	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000336	0.0026	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CALCA—thyroid cancer	0.000335	0.00259	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—AKT1—thyroid cancer	0.000329	0.00254	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—thyroid cancer	0.000326	0.00252	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000321	0.00248	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—AKT1—thyroid cancer	0.00031	0.00239	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—SST—thyroid cancer	0.000309	0.00239	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000298	0.0023	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CALCA—thyroid cancer	0.000298	0.0023	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CALCB—thyroid cancer	0.000293	0.00227	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NRG1—thyroid cancer	0.000292	0.00226	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000288	0.00223	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—BRAF—thyroid cancer	0.000286	0.00221	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000283	0.00218	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TRIM33—thyroid cancer	0.000278	0.00215	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—AKT1—thyroid cancer	0.000275	0.00212	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TERT—thyroid cancer	0.000262	0.00203	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CALCB—thyroid cancer	0.000261	0.00201	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TSHR—thyroid cancer	0.000253	0.00196	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HIF1A—thyroid cancer	0.000251	0.00194	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00025	0.00193	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TRIM33—thyroid cancer	0.000247	0.00191	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000236	0.00182	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TSHR—thyroid cancer	0.00023	0.00178	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000226	0.00175	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TSHR—thyroid cancer	0.000225	0.00174	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—NRAS—thyroid cancer	0.000221	0.00171	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—HRAS—thyroid cancer	0.000221	0.00171	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—BRAF—thyroid cancer	0.000208	0.0016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TSHR—thyroid cancer	0.000204	0.00158	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000201	0.00155	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000201	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—SST—thyroid cancer	0.000197	0.00152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTCH1—thyroid cancer	0.000195	0.00151	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000193	0.00149	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KRAS—thyroid cancer	0.00019	0.00147	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CALCA—thyroid cancer	0.000189	0.00146	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000189	0.00146	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TCF7L1—thyroid cancer	0.000186	0.00143	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—SST—thyroid cancer	0.000179	0.00138	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—SST—thyroid cancer	0.000175	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTCH1—thyroid cancer	0.000174	0.00134	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CALCA—thyroid cancer	0.000172	0.00133	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000172	0.00133	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000171	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CALCA—thyroid cancer	0.000168	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000166	0.00128	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TCF7L1—thyroid cancer	0.000165	0.00127	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRAS—thyroid cancer	0.000162	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—SST—thyroid cancer	0.000159	0.00123	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AKT1—thyroid cancer	0.000157	0.00121	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CDK1—thyroid cancer	0.000156	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CALCA—thyroid cancer	0.000153	0.00118	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HPGD—thyroid cancer	0.000152	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCND1—thyroid cancer	0.000152	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000148	0.00114	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTEN—thyroid cancer	0.000146	0.00113	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AKT1—thyroid cancer	0.000143	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000141	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CDK1—thyroid cancer	0.000138	0.00107	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSHR—thyroid cancer	0.000136	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000134	0.00103	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—HRAS—thyroid cancer	0.000132	0.00102	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NRAS—thyroid cancer	0.00013	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MEN1—thyroid cancer	0.000128	0.000986	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000125	0.000969	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSHR—thyroid cancer	0.000121	0.000932	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000119	0.000917	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTCH1—thyroid cancer	0.000115	0.000892	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MEN1—thyroid cancer	0.000113	0.000876	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—thyroid cancer	0.000112	0.000868	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SST—thyroid cancer	0.000106	0.000816	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTCH1—thyroid cancer	0.000103	0.000792	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CALCA—thyroid cancer	0.000102	0.000785	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—thyroid cancer	9.98e-05	0.000771	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—thyroid cancer	9.55e-05	0.000737	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SST—thyroid cancer	9.38e-05	0.000725	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDK1—thyroid cancer	9.2e-05	0.000711	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	9.03e-05	0.000698	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPR—thyroid cancer	8.73e-05	0.000675	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	8.59e-05	0.000664	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—thyroid cancer	8.43e-05	0.000651	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	8.17e-05	0.000631	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRG1—thyroid cancer	7.39e-05	0.000571	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—thyroid cancer	6.63e-05	0.000512	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	6.56e-05	0.000507	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	6.54e-05	0.000505	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HIF1A—thyroid cancer	6.34e-05	0.00049	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—thyroid cancer	5.89e-05	0.000455	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	5.63e-05	0.000435	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	5.59e-05	0.000432	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—RXRA—thyroid cancer	5.49e-05	0.000424	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	5.25e-05	0.000406	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	4.96e-05	0.000383	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	4.81e-05	0.000372	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	4.66e-05	0.00036	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	4.27e-05	0.00033	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	4.09e-05	0.000316	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	3.97e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	3.83e-05	0.000296	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	3.7e-05	0.000286	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	3.63e-05	0.00028	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	3.61e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	3.53e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPARG—thyroid cancer	3.47e-05	0.000268	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	3.4e-05	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	3.3e-05	0.000255	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	3.29e-05	0.000254	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	3.21e-05	0.000248	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	2.93e-05	0.000226	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	2.84e-05	0.000219	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.73e-05	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—thyroid cancer	2.52e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	2.52e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	2.41e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—thyroid cancer	2.38e-05	0.000184	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	2.24e-05	0.000173	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	2.14e-05	0.000166	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	2.13e-05	0.000165	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	1.89e-05	0.000146	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—thyroid cancer	1.37e-05	0.000106	CbGpPWpGaD
